文献速递MDS 与骨髓增殖性肿瘤造血干细胞移植与细胞治疗

不可分类骨髓增殖性肿瘤异基因造血干细胞移植结局:EBMT慢性恶性肿瘤工作组回顾性研究

Outcome of allogeneic haematopoietic stem cell transplantation in myeloproliferative neoplasm, unclassifiable: a retrospective study by the Chronic Malignancies Working Party of the EBMT.
PubMed 文献 · Br J Haematol · 2020-02-28

该研究由EBMT慢性恶性肿瘤工作组开展,回顾性分析不可分类骨髓增殖性肿瘤(MPN-U)患者接受异基因造血干细胞移植(allo-HCT)的结局。MPN-U临床表型与病程异质,缺乏共识管理指南,allo-HCT为唯一治愈手段但结局未明。本研究为迄今最大规模MPN-U移植回顾性研究,提供植入、GVHD及结局数据。

要点

  • MPN-U异质性强,无广泛共识管理指南,allo-HCT为唯一治愈策略。
  • 该研究为迄今最大规模MPN-U接受allo-HCT的回顾性研究。
  • 研究提供植入、GVHD及结局数据以助临床决策讨论。

核心结论

  • allo-HCT对MPN-U具有潜在治愈作用,但结局此前未充分明确。

研究设计与样本

  • EBMT慢性恶性肿瘤工作组开展的回顾性研究,为迄今最大规模MPN-U接受allo-HCT的队列。

临床怎么用

  • 研究提供植入、GVHD及结局数据,可辅助临床医生与MPN-U患者讨论allo-HCT。

局限性

  • 为回顾性研究设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Myeloproliferative Neoplasm (MPN), unclassifiable (MPN-U) is a heterogeneous disease with regards to both clinical phenotype and disease course. Patients may initially be asymptomatic or present with leucocytosis or thrombocytosis, anaemia, progressive splenomegaly, constitutional symptom, thromboses or accelerated/blastic phase disease. Treatment strategies are variable and there are no widely accepted consensus management guidelines for MNU-U. Allogeneic Haematopoietic Cell Transplantation (allo-HCT) remains the only curative strategy yet outcomes, to date, are not well defined. We hereby report on the largest retrospective study of patients with MPN-U undergoing allo-HCT, highlighting the potentially curative role and providing clinicians with robust engraftment, GvHD and outcome data to facilitate patient discussion.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. McLornan DP, Malpassuti V, Lippinkhof-Kozijn A, et al. Outcome of allogeneic haematopoietic stem cell transplantation in myeloproliferative neoplasm, unclassifiable: a retrospective study by the Chronic Malignancies Working Party of the EBMT. Br J Haematol. 2020. PMID: 32108327. doi:10.1111/bjh.16537

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。